The Swiss multinational pharmaceutical corporation Novartis AG has been cited in various instances recently like outperforming relative strength, overcoming Q2 estimates and achieving milestones in the course of their Cholesterol Drug's late-stage study. This induced interest from investors and short sellers as the stock was deemed as a cheap buy, consequently leading to surges in stock prices and raised guidance. Steps taken by Novartis in the biotech and pharmaceutical sectors have proved beneficial for its growth, backed by impressive sales from blockbuster drugs and raised guidance for 2024. Despite minor hurdles like underperforming prostate cancer drug sales, they've also indulged in strategic acquisitions, further expanding their pharmaceutical portfolio and boosting their earnings growth. Notably, reports are also highlighting Novartis' innovative approach, securing a 'Buy' rating by Goldman Sachs. This along with their international dividend popularity sets Novartis as a promising value and momentum stock for long-term investment.
Novartis Stocks News Analytics from Wed, 04 Oct 2023 07:00:00 GMT to Sat, 31 Aug 2024 02:21:15 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -2
